Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Tamminga, Ca
1997.
The Promise of New Drugs for Schizophrenia Treatment.
The Canadian Journal of Psychiatry,
Vol. 42,
Issue. 3,
p.
265.
Buckley, Peter F.
1997.
New Dimensions in the Pharmacologic Treatment of Schizophrenia and Related Psychoses.
The Journal of Clinical Pharmacology,
Vol. 37,
Issue. 5,
p.
363.
Waddington, John L.
Scully, Paul J.
and
O'Callaghan, Eadbhard
1997.
The new antipsychotics, and their potential for early intervention in schizophrenia.
Schizophrenia Research,
Vol. 28,
Issue. 2-3,
p.
207.
Walters, Verónica Larach
Tognolini, Renzo Zamboni
Rueda, Humberto Mancini
Rueda, Roberto Mancini
and
Torres, Roberto Gallardo
1997.
New strategies for old problems: tardive dyskinesia (TD) Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up.
Schizophrenia Research,
Vol. 28,
Issue. 2-3,
p.
231.
King, David J
1998.
Drug treatment of the negative symptoms of schizophrenia.
European Neuropsychopharmacology,
Vol. 8,
Issue. 1,
p.
33.
Kasper, S
Tauscher, J
Küfferle, E
Hesselmann, B
Barnas, C
and
Brücke, T
1998.
IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics.
European Psychiatry,
Vol. 13,
Issue. S1,
p.
9s.
Galatsis, Paul
1998.
Vol. 33,
Issue. ,
p.
327.
Kasper, S
Tauscher, J
Küfferle, E
Hesselmann, B
Barnas, C
and
Brücke, T
1998.
IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics.
European Psychiatry,
Vol. 13,
Issue. ,
p.
9s.
Kasper, S.
1998.
Neuro-Psychopharmaka Ein Therapie-Handbuch.
p.
489.
King, David J.
1998.
Atypical antipsychotics and the negative symptoms of schizophrenia.
Advances in Psychiatric Treatment,
Vol. 4,
Issue. 1,
p.
53.
Fleischhacker, W. W.
1999.
Search for the Causes of Schizophrenia.
p.
331.
Blin, Olivier
1999.
A Comparative Review of New Antipsychotics.
The Canadian Journal of Psychiatry,
Vol. 44,
Issue. 3,
p.
235.
Schmauß, M.
1999.
Atypische Neuroleptika.
p.
57.
Green, Ben
1999.
Focus on Quetiapine.
Current Medical Research and Opinion,
Vol. 15,
Issue. 3,
p.
145.
Markowitz, John S
Brown, Candace S
and
Moore, Thea R
1999.
Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy.
Annals of Pharmacotherapy,
Vol. 33,
Issue. 1,
p.
73.
Leucht, S.
Pitschel-Walz, G.
Abraham, D.
and
Kissling, W.
1999.
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Schizophrenia Research,
Vol. 35,
Issue. 1,
p.
51.
Fleischhacker, W. W.
2000.
Psychiatrie der Gegenwart 5.
p.
209.
Möller, Hans-Jürgen
2000.
Definition, Psychopharmacological Basis and Clinical Evaluation of Novel/Atypical Neuroleptics: Methodological Issues and Clinical Consequences.
The World Journal of Biological Psychiatry,
Vol. 1,
Issue. 2,
p.
75.
Srisurapanont, M
Disayavanish, C
and
Taimkaew, K
2000.
Cochrane Database of Systematic Reviews.
Yeung, Paul P
Tariot, Pierre N
Schneider, Lon S
Salzman, Carl
and
Rak, Ihor W
2000.
Quetiapine for Elderly Patients With Psychotic Disorders.
Psychiatric Annals,
Vol. 30,
Issue. 3,
p.
197.
eLetters
No eLetters have been published for this article.